跳至主要内容
临床试验/NCT00937261
NCT00937261Unknown4 期

Contrasting the Brain Effects of Risperidone and Invega With fMRI and PET Scanning

University of California, Irvine1 个研究点 分布在 1 个国家目标入组 96 人开始时间: 2009年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
96
试验地点
1
主要终点
Comparison of BOLD signal activation and FDG metabolism of the DLPFC, superior temporal gyrus and amygdala, and their interaction between Invega and Risperdal

研究概览

简要总结

The purpose of this study is to better understand brain function and psychiatric and neurological illness when taking Invega or Risperdal. The objective is to compare the brain effects of Invega to Risperdal in patients with Schizophrenia. This comparison will be evaluated with PET imaging, fMRI, and neurological ratings and assessments.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者
否

入选标准

  • •are currently taking Risperdal and have been on the medication for at least three weeks
  • •are diagnosed with schizophrenia
  • •are able to provide written informed consent
  • •can safely have an MRI

排除标准

  • •are treatment resistant or intolerant to Risperdal
  • •have participated in another drug study in the past 28 days
  • •are pregnant or trying to become pregnant or are breastfeeding
  • •are colorblind
  • •have a history of alcohol, cannabis, or cocaine abuse within two weeks prior to the study
  • •have a current or past history of a major medical illness or have abnormal lab values which the study doctor feels is significant
  • •certain medications are also exclusionary including aripiprazole.

研究组 & 干预措施

Risperdal

Experimental

Risperdal 2-8mg per day

干预措施: Risperidone (Drug)

Invega

Experimental

Invega 6-12mg per day

干预措施: Paliperidone (Drug)

结局指标

主要结局

Comparison of BOLD signal activation and FDG metabolism of the DLPFC, superior temporal gyrus and amygdala, and their interaction between Invega and Risperdal

时间窗: approximately 6-10 weeks

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验